{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004422","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.147079+00:00","generated_at":"2026-05-31T13:19:27.294525+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioCryst Q2 ORLADEYO revenue up 34% to $108.3M; raises FY guidance to $420-435M","bullets":["Q2 total revenue $109.3M (+32.5% YoY); GAAP operating profit $8.8M vs loss $20.7M in Q2 2023.","Net loss narrowed to $12.7M ($0.06/share) from $75.3M ($0.40/share); non-GAAP operating profit $21.9M.","ORLADEYO FY2024 revenue guidance raised to $420-435M from $390-400M, citing strong demand and payer improvements.","Discontinuing oral Factor D inhibitor BCX10013 due to insufficient activity; advancing BCX17725 for Netherton syndrome to clinic by end-2024.","Cash $338.1M vs $415.7M a year ago; operating cash use was only $0.2M in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004422","json":"https://secwatch.observer/filing/0001171843-24-004422.json","markdown":"https://secwatch.observer/filing/0001171843-24-004422.md","text":"https://secwatch.observer/filing/0001171843-24-004422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324004422/0001171843-24-004422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324004422/f8k_080524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:19:27.294525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}